{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967683",
  "id": "02967683",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0916",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmmyp3mdr0s8.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Acquisition of Galidesivir Program**  \n  - **Seller:** BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX)  \n  - **Purchase Price:** **US$550,000 upfront** (includes US$50,000 option fee).  \n  - **Milestone Payments:**  \n    - **US$500,000** upon Phase 2 trial completion.  \n    - **US$1M** upon standard FDA approval, **US$1.5M** if approved via Animal Rule (no Phase 2 required).  \n    - **Royalties:** 5-10% on net sales.  \n    - **25% of proceeds** from any Priority Review Voucher (PRV) sale.  \n\n- **Regulatory Pathway & Value Driver:**  \n  - Targeting **FDA Animal Rule approval** for **Marburg virus**, potentially requiring only **one additional animal study** before NDA.  \n  - Potential **Priority Review Voucher (PRV)** post-approval (recent PRVs sold for **US$100\u2013150M**).  \n\n- **Galidesivir Profile:**  \n  - Broad-spectrum antiviral (Ebola, Marburg, MERS, Zika, Yellow Fever).  \n  - **US$70M+** in prior US government-funded R&D.  \n  - **Phase 1 trials** completed (safety data available).  \n\n- **Funding & Cash Position:**  \n  - Funded via **existing cash** (last reported **A$4.82M + A$3.6M placement**).  \n  - Upfront cost covered; future trials funded from available capital.  \n\n- **Upcoming Catalyst:**  \n  - **Marburg animal study** expected **within 12 months**.  \n\n**No material capital raising or trading halt information identified.**  \n\n*(Omitted: Webinar details, historical background, non-core management commentary.)*",
  "usage": {
    "prompt_tokens": 3933,
    "completion_tokens": 403,
    "total_tokens": 4336,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:33:51.387534"
}